Pharmaceuticals, Biotechnology and Life Sciences
Amryt has expanded its market coverage for Lojuxta with an exclusive distribution agreement for Lebanon, Jordan and Syria, as it…
Amryt has signed an exclusive distribution agreement for Lojuxta (lomitapide) covering Romania and Bulgaria with Romastru Trading SRL (Romastru), a…
Amryt has paved its way for marketing for Lojuxta by signing a deal with with GryNumber Health. The exclusive distribution…
Amryt, a biopharmaceutical company focused on rare and orphan diseases, has signed an agreement for distributing its Lojuxta through RCC…
Amryt Pharma has published a long-term extension study of Lojuxta in treating a rare, genetic, life-threatening disease, Homozygous Familial Hypercholesterolaemia (HoFH), which followed patients for up to 5.7 years results, showed Lojuxta as being highly effective in lowering LDL-C levels, with acceptable tolerability and no new safety signals.